Arcus Biosciences Inc (RCUS) is a biotechnology company focused on discovering and developing precision therapies for the treatment of cancer. In order to make informed investment decisions, it is important to utilize technical analysis tools to evaluate the stock's performance. Let's explore some key technical indicators for RCUS.

One popular technical indicator is the Relative Strength Index (RSI), which measures the magnitude of recent price changes to determine overbought or oversold conditions. By analyzing the RCUS stock RSI, investors can assess whether the stock is overbought or oversold and make appropriate trading decisions.

Arcus Biosciences  (RCUS) Technical Analysis

Learn about the technical analysis indicators for Arcus Biosciences Inc (RCUS) stock including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the stock's performance and make informed investment decisions.

Arcus Biosciences Inc (RCUS) Technical Analysis and Indicators

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences 

NYSE

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	45.83	Neutral	125.8%
auto_graphMACD	-2.04	Neutral	176.1%
auto_graphCCI	-26.86	Neutral	24.3%
auto_graphADX	3.60	Neutral	-
auto_graphATR	5.20	Buy	-
auto_graphWILLR	-72.90	Neutral	102.9%
auto_graphROC	16.61	Neutral	-40.7%
auto_graphSTOCHRSI	49.02	Neutral	64.4%

Buy	1	12.50%
Hold	7	87.50%
Sell	0	0.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Arcus Biosciences (RCUS) Technical Analysis

Keep an eye on Arcus Biosciences

Frequently Asked Questions

What are the technical signals for Arcus Biosciences (RCUS) stock based on the last 30 days?

Sign up for our newsletter

Take Your Investments to a Whole New Level